TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9579445
Drug: dl-norgestrel (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: dl-norgestrel (0.05 mg/day)
Study: 9579445
Drug: medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: medroxyprogesterone acetate (2.5 mg/day)
Study: 2633927
Drug: Colchicine tablets
Normalized name: Colchicine Tablets
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine tablets (A)
Study: 2633927
Drug: Colchicine oral
Normalized name: colchicine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine oral solution (B)
Study: 7377746
Drug: Sulfadiazine (SD)
Normalized name: Sulfadiazine
DrugBank: Sulfadiazine (DB00359)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfadiazine (SD) 4 mg/kg twice a day, loading dose 8 mg/kg
Study: 7377746
Drug: Fulfafurazole (SF)
Normalized name: sulfafurazole
DrugBank: Sulfisoxazole (DB00263)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fulfafurazole (SF) 50 mg/kg four times a day
Study: 30945088
Drug: Liberal fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal fluid strategy (12 ml/kg/h)
Study: 30945088
Drug: Restricted fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restricted fluid strategy (4 ml/kg/h)
Study: 25829263
Drug: Educational booklet
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational booklet on anticoagulant treatment with warfarin
Study: 23661293
Drug: Concurrent oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Concurrent oxaliplatin 70 mg/m² weekly for six cycles
Study: 10989730
Drug: diltiazem 300
Normalized name: diltiazem 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: diltiazem 300 mg/daily
Study: 10989730
Drug: amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: amlodipine 10 mg/daily
Study: 1285740
Drug: Adjuvant cisplatin-based
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvant cisplatin-based chemotherapy (n = 97)
Study: 1285740
Drug: Chemotherapy for
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy for recurrent disease (n = 83)
Study: 1285740
Drug: Adjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant treatment group (control group)
Study: 1285740
Drug: Both chemotherapy
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both chemotherapy groups (adjuvant and recurrent)
Study: 3934402
Drug: 2.2 g
Normalized name: Vaporizer Safeguard 2.2 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.2 g protein/kg/day
Study: 3934402
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g protein/kg/day
Study: 20812862
Drug: Pentaerythritol tetranitrate
Normalized name: Pentaerythritol tetranitrate
DrugBank: Pentaerythritol tetranitrate (DB06154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentaerythritol tetranitrate (PETN) 80 mg orally two times per day for 14 days
Study: 20812862
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) 40 mg retarded release orally two times per day for 14 days
Study: 16981945
Drug: Topical misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical misoprostol
Study: 27086023
Drug: Ongoing PRN
Normalized name: Ongo-Fin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ongoing PRN ranibizumab monotherapy (n = 119)
Study: 23227680
Drug: Meridian cosmetology
Normalized name: sibutramine hydrochloride Oral Capsule [Meridia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meridian cosmetology treatment (including acupuncture at specific body acupoints and local needling therapy)
Study: 23227680
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication (oral administration of Vitamin C and E for 3 months)
Study: 23227680
Drug: Meridian cosmetology
Normalized name: sibutramine hydrochloride Oral Capsule [Meridia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meridian cosmetology treatment
Study: 20978028
Drug: QVA149 (indacaterol/NVA237)
Approvals — FDA: no, EMA: no, PMDA: no
Description: QVA149 (indacaterol/NVA237) 300/50 μg
Study: 18617080
Drug: Behavioral intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Behavioral intervention (20 weekly group sessions encouraging calorie restriction, moderate-intensity physical activity, and the DASH dietary pattern)
Study: 1655219
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus involved-field radiation therapy (24 patients)
Study: 1655219
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (24 patients)
Study: 30725289
Drug: Magnetic steering
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnetic steering of capsule endoscopy
Study: 19214661
Drug: Prokinetic agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prokinetic agent (mosapride 15 mg, orally three times daily) for 4 weeks
Study: 11445849
Drug: Tegafur (FT)
Normalized name: tegafur
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Tegafur (FT) alone or FT plus low doses of cisplatin
Study: 11360524
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate (BDP) 1000 micrograms daily for 6 weeks
Study: 3045746
Drug: Cimetidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1 g daily, 3 tablets during the day and 2 tablets at night)
Study: 26394270
Drug: Glatiramer acetate
Normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glatiramer acetate 40 mg/mL three times weekly subcutaneous injection (GA40)
Study: 21559038
Drug: 10 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g/d BSP (n=21)
Study: 21559038
Drug: 5 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g/d BSP (n=22)
Study: 17964616
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein preload (300 mL, 1 MJ)
Study: 14668455
Drug: Three-drug regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-drug regimen containing efavirenz combined with zidovudine and lamivudine
Study: 10710885
Drug: Intraglobin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraglobin (400 mg/kg/d x 5)
Study: 10710885
Drug: Venoglobulin-I (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venoglobulin-I (1 g/kg/d x 2)
Study: 8726950
Drug: Inhaled glucocorticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled glucocorticosteroids (standard pediatric doses)
Study: 1340901
Drug: Subcutaneous Continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Continuous Preprogrammed Insulin Infusion (SCII)
Study: 1340901
Drug: Multiple Conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple Conventional Insulin Injections (MCII)
Study: 6502211
Drug: Naloxone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (2 mg, i.v.)
Study: 29890270
Drug: MCC (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCC (60 mL·d‐1)
Study: 25333925
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of OECs and SCs
Study: 19889796
Drug: Ketoconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (200 mg b.i.d.)
Study: 19889796
Drug: Fluconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (400 mg once a day)
Study: 16437366
Drug: Intraoperative peritoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative peritoneal hyperthermic chemotherapy (IPHC)
Study: 10384736
Drug: Understanding of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Understanding of materials requiring attribution of mental states (e.g. ignorance, false belief)
Study: 1648488
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg isosorbide-5-mononitrate (ISMN)
Study: 6583715
Drug: Des-Tyr-gamma-endorphin (DT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Des-Tyr-gamma-endorphin (DT gamma E) 1 mg, i.m., for 8 consecutive days
Study: 27703328
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg intrathecal pethidine (P5 group)
Study: 27703328
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg intrathecal pethidine (P10 group)
Study: 27703328
Drug: Standard group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard group (S group) with 0.5 mL of 0.9% saline
Study: 18632147
Drug: Abatacept (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abatacept (10 mg/kg intravenously at 28-day intervals for 6 months)
Study: 18632147
Drug: Placebo (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10 mg/kg at 28-day intervals for 6 months)
Study: 15924546
Drug: Oral antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotics given prior to delivery
Study: 2499342
Drug: GTN spray
Normalized name: GTN
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTN spray (Nitro‐Corangin Spray)
Study: 2499342
Drug: Another GTN
Normalized name: GTN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Another GTN Spray
Study: 28007678
Drug: ERA+probiotic (Bifidobacterium
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERA+probiotic (Bifidobacterium animalis subsp. lactis B94, 1 capsule/day)
Study: 28007678
Drug: ERA+placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERA+placebo (1 capsule/day)
Study: 28007678
Drug: ERA-only (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERA-only (no additional treatments)
Study: 19474651
Drug: Atazanavir/ritonavir (ATV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir/ritonavir (ATV/r) 300 mg and ritonavir 100 mg daily for 6 months
Study: 15470330
Drug: Fluconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (200 mg daily)
Study: 8489563
Drug: 1000 mg/day
Normalized name: RibaTab 1000 MG/day Compliance Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg/day HR
Study: 8489563
Drug: 500 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/day HR
Study: 2881132
Drug: Penicillin (10(6)
Normalized name: Penicillin V
DrugBank: Meticillin (DB01603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin (10(6) IU three times daily for 6 days)
Study: 19463347
Drug: Percutaneous coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous coronary intervention plus medical therapy (PCI+MT)
Study: 19463347
Drug: Initial medical
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial medical therapy only (MT)
Study: 16627442
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral bolus propafenone (600 mg)
Study: 16627442
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral bolus therapy (no bolus)
Study: 16627442
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral bolus placebo
Study: 8434380
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy without diltiazem (ND)
Study: 3319120
Drug: L‐DOPA/carbidopa (Sinemet)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐DOPA/carbidopa (Sinemet)
Study: 23153177
Drug: Liraglutide added
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide added to insulin therapy
Study: 23153177
Drug: Insulin dose-increase
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin dose-increase
Study: 18729731
Drug: Combined folic
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined folic acid and B-vitamin therapy
Study: 12518724
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy with antioxidants (vitamin E 200 mg/d and polyunsaturated fatty acids 1,000 mg/d)
Study: 12518724
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy only (no antioxidants)
Study: 12518724
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy with antioxidants
Study: 12518724
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy only
Study: 8172090
Drug: 10 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g/d fiber supplement
Study: 8172090
Drug: 20 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g/d fiber supplement
Study: 23924679
Drug: 4 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 × 25-mg non-coated tablets
Study: 23924679
Drug: 100-mg tablet
Normalized name: dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100-mg tablet dispersed in 100 ml water
Study: 23924679
Drug: 200-mg non-coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200-mg non-coated and coated tablets
Study: 23924679
Drug: 100-mg tablets
Normalized name: dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100-mg tablets
Study: 16487836
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of captopril and valsartan
Study: 10767065
Drug: Three-dimensional contrast-enhanced
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-dimensional contrast-enhanced moving-bed infusion-tracking (MoBI-track) peripheral MR angiography
Study: 1737593
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clinical and mammographic measurements
Study: 6378516
Drug: Prostaglandin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin treatment at home (9‐deoxo‐16, 16‐dimethyl‐9‐methylene‐PGE2, 50 to 60 mg twice at 6‐hour intervals)
Study: 6378516
Drug: Prostaglandin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin treatment in hospital (9‐deoxo‐16, 16‐dimethyl‐9‐methylene‐PGE2, 50 to 60 mg twice at 6‐hour intervals)
Study: 29073780
Drug: CWI with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CWI with ropivacaine 2 mg/mL at a rate of 2 mL/h for 24 hours
Study: 23012417
Drug: Dynamic reconfiguration
Normalized name: water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic reconfiguration of brain network during task preparation
Study: 20974610
Drug: Riboflavin 50
Normalized name: riboflavin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riboflavin 50 mg/day
Study: 17949466
Drug: Nicotine (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (low dose 7 mg)
Study: 17949466
Drug: Nicotine (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (high dose 14 or 21 mg)
Study: 16236688
Drug: Fluvoxamine 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine 200 mg/day
Study: 10425951
Drug: Ketorolac tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac tromethamine (10 mg p.o.)
Study: 10425951
Drug: Acetaminophen codeine
Normalized name: acetaminophen / codeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen codeine (325 mg/15 mg p.o.)
Study: 7498204
Drug: Propranolol (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (120 mg.day‐1 in twice divided doses)
Study: 2405720
Drug: Oral tetrahydroaminoacridine
Normalized name: Tetrahydroaminoacridine
DrugBank: Tacrine (DB00382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tetrahydroaminoacridine (THA) and lecithin
Study: 2405720
Drug: Long-term treatment
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term treatment with THA and lecithin
Study: 31821591
Drug: Efgartigimod 5
Normalized name: Efgartigimod alfa
DrugBank: Efgartigimod alfa (DB15270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Efgartigimod 5 mg/kg
Study: 24008684
Drug: Internet-based preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based preparation for inpatient psychosomatic psychotherapeutic treatment (VORSTAT)
Study: 21458107
Drug: Enteric-coated mycophenolate
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteric-coated mycophenolate sodium (EC-MPS) 1440 mg
Study: 11054648
Drug: IGF-I (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGF-I (80 microg/kg body weight, daily two s.c. injections for five days)
Study: 9113634
Drug: HI20:4 diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: HI20:4 diet (1.7 g/d arachidonic acid)
Study: 9113634
Drug: LO20:4 diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: LO20:4 diet (0.21 g/d arachidonic acid)
Study: 3532439
Drug: Trazodone hydrochloride
Normalized name: Trazodone Hydrochloride
DrugBank: Trazodone (DB00656)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trazodone hydrochloride 10 mg intravenously every 12 hours for seven days
Study: 18498362
Drug: Two-implant overdenture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-implant overdenture (IOD)
Study: 28426476
Drug: Intrasphincteric injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrasphincteric injections of autologous myoblasts (AM)
Study: 28426476
Drug: Delayed frozen
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed frozen AM injection in placebo group
Study: 22012130
Drug: High-dose recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose recombinant human erythropoietin (rHuEPO) 40,000 units
Study: 21118924
Drug: Monthly SP
Normalized name: SPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly SP
Study: 21118924
Drug: AZI-SP (monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZI-SP (monthly SP and two doses of azithromycin)
Study: 21118924
Drug: Controls (sulfadoxine‐pyrimethamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controls (sulfadoxine‐pyrimethamine twice)
Study: 17541591
Drug: Vinorelbine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine 30 mg/m2 i.v.
Study: 17541591
Drug: Vinorelbine 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine 80 mg/m2 oral
Study: 17541591
Drug: Both oral
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both oral and i.v. forms
Study: 9585289
Drug: Lidocaine plus
Normalized name: Icy Hot Lidocaine Plus Menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine plus 0.2 mg of epinephrine (Group B)
Study: 9585289
Drug: Lidocaine plus
Normalized name: Icy Hot Lidocaine Plus Menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine plus 0.4 mg of epinephrine (Group C)
Study: 9585289
Drug: Lidocaine plus
Normalized name: Icy Hot Lidocaine Plus Menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine plus 0.6 mg of epinephrine (Group D)
Study: 7712756
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (0.1 mg/kg/day)
Study: 2667704
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine (52 mg/nasal cavity)
Study: 827772
Drug: Physostigmine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine (3 mg total dose, intravenously)
Study: 18613931
Drug: Simulation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simulation of an infusion of 1 mug.kg(‐1) over 10 min followed by an infusion of 0.7 mug.kg(‐1).h(‐1) for 50 min
Study: 15760322
Drug: Weekly intramuscular
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly intramuscular methotrexate at 30 mg/m(2)
Study: 15760322
Drug: Intravenous dactinomycin
Normalized name: Dactinomycin
DrugBank: Dactinomycin (DB00970)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous dactinomycin at 1.25 mg/m(2) every 2 weeks
Study: 10567783
Drug: Gemifloxacin 320
Normalized name: gemifloxacin 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemifloxacin 320 mg o.d. for 7 days
Study: 10567783
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg b.d. for 7 days
Study: 10567783
Drug: Gemifloxacin 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemifloxacin 160 mg o.d. for 7 days
Study: 387068
Drug: Ritodrine hydrochloride
Normalized name: Ritodrine Hydrochloride
DrugBank: Ritodrine (DB00867)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ritodrine hydrochloride 40 mg by mouth daily
Study: 23944300
Drug: Faldaprevir 120
Normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faldaprevir 120 mg once daily and Deleobuvir 600 mg three times daily plus ribavirin for 16 weeks (TID16W)
Study: 23944300
Drug: Faldaprevir 120
Normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faldaprevir 120 mg once daily and Deleobuvir 600 mg three times daily plus ribavirin for 28 weeks (TID28W)
Study: 23944300
Drug: Faldaprevir 120
Normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faldaprevir 120 mg once daily and Deleobuvir 600 mg three times daily plus ribavirin for 40 weeks (TID40W)
Study: 23944300
Drug: Faldaprevir 120
Normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faldaprevir 120 mg once daily and Deleobuvir 600 mg twice daily plus ribavirin for 28 weeks (BID28W)
Study: 23944300
Drug: Faldaprevir 120
Normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faldaprevir 120 mg once daily and Deleobuvir 600 mg three times daily without ribavirin for 28 weeks (TID28W‐NR)
Study: 9953
Drug: Intramuscular diamorphine
Normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular diamorphine